Genetically modified microorganism for producing 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid, and method for producing said chemicals

Genetically modifying microorganisms to enhance the glyoxylic acid cycle and reduce by-product production improves the yield of 3-hydroxyadipic acid, α-hydromuconic acid, and adipic acid, addressing the issue of by-product interference in microbial production processes.

WO2024242124A1PCT designated stage expired Publication Date: 2024-11-28TORAY INDUSTRIES INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/018765
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-23
Filing Date
2024-05-22
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current methods for producing 3-hydroxyadipic acid, α-hydromuconic acid, and adipic acid using microorganisms face challenges in suppressing by-products like acetic acid, which reduces the productivity of the target substances.

Method used

A genetically modified microorganism with a strengthened glyoxylic acid cycle, reduced lactic acid or ethanol production, and enhanced enzymatic activity to improve the production of 3-hydroxyadipic acid, α-hydromuconic acid, and adipic acid while minimizing acetic acid production.

Benefits of technology

The approach increases the productivity of 3-hydroxyadipic acid, α-hydromuconic acid, and adipic acid while reducing acetic acid production, thereby enhancing the production ratio of these target substances.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JPOXMLDOC01-APPB-C000001
    Figure JPOXMLDOC01-APPB-C000001
  • Figure JPOXMLDOC01-APPB-C000002
    Figure JPOXMLDOC01-APPB-C000002
  • Figure JPOXMLDOC01-APPB-C000003
    Figure JPOXMLDOC01-APPB-C000003
Patent Text Reader

Abstract

Abstract: Disclosed is a novel genetically modified microorganism capable of reducing the productivity of acetic acid, which is a main by-product, and improving the productivity of 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid, in a method for producing 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid using a microorganism. The genetically modified microorganism is one in which the glyoxalate cycle is enhanced and the lactic acid or ethanol generation reaction is reduced in a microorganism having the ability to produce 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid.
Need to check novelty before this filing date? Find Prior Art

Description

Genetically modified microorganisms for producing 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid and methods for producing said chemicals

[0001] The present invention relates to a genetically modified microorganism that produces 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid at high levels, and a method for producing 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid using the genetically modified microorganism.

[0002] 3-Hydroxyadipic acid (IUPAC name: 3-hydroxyhexanediioic acid), α-hydromuconic acid (IUPAC name: (E)-hex-2-enedioic acid), and adipic acid (IUPAC name: hexanedioic acid) are dicarboxylic acids with six carbon atoms. These can be polymerized with polyhydric alcohols to form polyesters, and with polyamines to form polyamides. Lactamized compounds obtained by adding ammonia to the terminals of these compounds can also be used as polyamide raw materials.

[0003] As a document related to the production of 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid using a microorganism, Patent Document 1 describes a method for producing 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid using a polypeptide that exhibits excellent activity in catalyzing the reduction reaction of 3-oxoadipyl-CoA to 3-hydroxyadipyl-CoA, and describes that the biosynthetic pathway for these substances goes through an enzymatic reaction that reduces 3-oxoadipyl-CoA to 3-hydroxyadipyl-CoA.

[0004] Patent Document 2 describes a method for producing 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid using a polypeptide that exhibits excellent activity in catalyzing the reduction reaction of 3-oxoadipyl-CoA to 3-hydroxyadipyl-CoA and a genetically modified microorganism that has been rendered deficient in pyruvate kinase function.

[0005] Patent Document 3 describes a method for producing 3-hydroxyadipic acid and / or α-hydromuconic acid using a genetically modified microorganism in which the reaction for producing acetyl-CoA from pyruvate is enhanced and the function of pyruvate kinase and / or phosphotransferase enzymes is reduced.

[0006] Incidentally, in the production of chemical products using microorganisms, suppressing by-products and improving productivity of target substances is a common technical challenge. In the production of 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid using microorganisms, acetic acid is a major by-product, as shown in Patent Document 2. Therefore, if the by-production of acetic acid by microorganisms capable of producing 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid can be reduced, it can be expected that the productivity of 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid by these microorganisms will be improved.

[0007] However, it is also known that in the production of chemical products using microorganisms, blocking the acetic acid production pathway to reduce the by-production of acetic acid also reduces the productivity of the target substance. Specifically, one method for blocking the acetic acid production pathway is to inactivate or delete genes encoding enzymes that catalyze the acetic acid production reaction. Known main enzymes that catalyze the acetic acid production reaction include phosphate acetyltransferase (EC 2.3.1.8), which catalyzes the reaction that produces acetyl phosphate and CoA from acetyl-CoA and phosphate, acetate kinase (EC 2.7.2.1), which catalyzes the reaction that produces acetic acid from acetyl phosphate, and pyruvate dehydrogenase (EC 1.2.5.1), which catalyzes the reaction that produces acetic acid and carbon dioxide from pyruvic acid. However, as exemplified in Non-Patent Document 1, it is known that in industrially widely used Escherichia coli, deletion of the genes ackA, pta, and poxB, which encode the enzymes that catalyze the acetic acid production reaction, reduces the growth of the microorganism, and therefore reduces the productivity of the target substance.

[0008] WO2019 / 107516 WO2020 / 230718 WO2022 / 102635 Special table 2008-513023

[0009] Front. Microbiol. 2020, 11, 233. BMC Microbiology 2011, 11:70.

[0010] An object of the present invention is to provide a genetically modified microorganism capable of producing 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid, which can improve productivity of 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid while reducing the by-production of acetic acid by modifying the metabolic pathway of the microorganism without blocking the acetic acid production pathway.

[0011] As a result of intensive research conducted by the present inventors to achieve the above-mentioned object, they found that in a microorganism capable of producing 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid, the productivity of 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid is improved and the productivity of acetic acid is reduced by enhancing the glyoxylic acid cycle and reducing the lactic acid or ethanol production reaction, and thus completed the present invention.

[0012] Specifically, the present invention comprises the following (1) to (16):

[0013] (1) A genetically modified microorganism capable of producing 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid, in which the glyoxylate cycle is enhanced and the lactic acid or ethanol production reaction is reduced. (2) The genetically modified microorganism according to (1), in which the enhancement of the glyoxylate cycle is a reduction in the function of the isocitrate lyase repressor, an enhancement of the function of malate synthase, and / or an enhancement of the function of isocitrate dehydrogenase kinase / phosphatase. (3) The genetically modified microorganism according to (1) or (2), in which the enhancement of the glyoxylate cycle is any of the following (i) to (iii): (i) a reduction in the function of the isocitrate lyase repressor by deletion, loss-of-function mutation, or suppression of expression of the iclR gene, (ii) an enhancement of the function of malate synthase by increasing the expression level of the aceB gene, or (iii) an enhancement of the function of isocitrate dehydrogenase kinase / phosphatase by increasing the expression level of the aceK gene. (4) The genetically modified microorganism according to any one of (1) to (3), wherein the decrease in the lactic acid production reaction is due to deletion, loss-of-function mutation, or expression suppression of a gene encoding lactate dehydrogenase. (5) The genetically modified microorganism according to (4), wherein the gene encoding lactate dehydrogenase is the ldhA gene. (6) The genetically modified microorganism according to any one of (1) to (5), wherein the decrease in the ethanol production reaction is due to deletion, loss-of-function mutation, or expression suppression of a gene encoding alcohol dehydrogenase. (7) The genetically modified microorganism according to (6), wherein the gene encoding alcohol dehydrogenase is the adhE gene. (8) The genetically modified microorganism according to any one of (1) to (7), further comprising an enhanced reaction for reducing 3-oxoadipyl-CoA to produce 3-hydroxyadipyl-CoA. (9) The genetically modified microorganism according to (1), wherein a reaction pathway for producing acetic acid from acetyl-CoA or pyruvate is maintained. (10) A method for producing 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid, comprising culturing the genetically modified microorganism according to any one of (1) to (9).(11) A method for producing adipic acid, comprising the steps of producing 3-hydroxyadipic acid and / or α-hydromuconic acid by the method described in (10) and reacting with hydrogen in the presence of a hydrogenation catalyst (hydrogenation step). (12) A method for producing polyamide, comprising the steps of producing adipic acid by the method described in (10) or (11) and polycondensing adipic acid and a diamine. (13) The method for producing polyamide according to (12), wherein the diamine is a diamine containing 1,4-butanediamine, 1,5-pentanediamine, or hexamethylenediamine. (14) 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid obtained by culturing the genetically modified microorganism according to any one of (1) to (9). (15) Adipic acid obtained by a process comprising the steps of producing 3-hydroxyadipic acid and / or α-hydromuconic acid by the method described in (10) and reacting them with hydrogen in the presence of a hydrogenation catalyst (hydrogenation step). (16) Polyamide obtained by a process comprising the steps of producing adipic acid by the method described in (10) or (11) and polycondensing adipic acid and a diamine.

[0014] The genetically modified microorganism according to the present invention can increase the productivity of 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid and decrease the productivity of acetic acid, compared to a parent strain microorganism in which the gene has not been modified. That is, the production ratio of 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid relative to acetic acid can be increased.

[0015] The present invention will be described in more detail below, but the present invention is not limited to the following embodiments and can be implemented with various modifications within the scope of the gist of the present invention.

[0016] Hereinafter, in this specification, 3-hydroxyadipyl-CoA may be abbreviated as "3HA," α-hydromuconic acid as "HMA," and adipic acid as "ADA." Also, 3-oxoadipyl-CoA may be abbreviated as "3OA-CoA," 3-hydroxyadipyl-CoA as "3HA-CoA," 2,3-dehydroadipyl-CoA as "HMA-CoA," and adipyl-CoA as "ADA-CoA." Furthermore, the enzyme that catalyzes the reaction of reducing 3-oxoadipyl-CoA to produce 3-hydroxyadipyl-CoA may be referred to as "3-oxoadipyl-CoA reductase." Isocitrate lyase repressor may be referred to as "IclR," malate synthase as "AceB," and isocitrate dehydrogenase kinase / phosphatase as "AceK." Nucleic acids that encode functional polypeptides may be referred to as genes.

[0017] The genetically modified microorganism of the present invention can biosynthesize 3HA, HMA, and / or ADA using acetyl-CoA and succinyl-CoA as intermediates, as shown in the following metabolic pathway: The metabolic pathway from glucose to acetyl-CoA is glycolysis, and the metabolic pathway from glucose to succinyl-CoA is well known as a metabolic pathway consisting of the TCA cycle, the glyoxylate cycle, and the supplementary pathway that produces oxaloacetate from PEP, as well as the reductive TCA cycle.

[0018]

[0019] The chemical formulas of the metabolic products of the metabolic pathway that produces 3HA, HMA, and / or ADA from acetyl-CoA and succinyl-CoA are shown below. Here, reaction A represents the reaction that produces 3-oxoadipyl-CoA from acetyl-CoA and succinyl-CoA. Reaction B represents the reaction that produces 3-hydroxyadipyl-CoA by reduction of 3-oxoadipyl-CoA. Reaction C represents the reaction that produces 2,3-dehydroadipyl-CoA from 3-hydroxyadipyl-CoA. Reaction D represents the reaction that produces adipyl-CoA from 2,3-dehydroadipyl-CoA. Reaction E represents the reaction that produces 3-hydroxyadipyl-CoA from 3-hydroxyadipyl-CoA. Reaction F represents the reaction that produces α-hydromuconic acid from 2,3-dehydroadipyl-CoA. Reaction G shows a reaction for producing adipic acid from adipyl-CoA. Enzymes that catalyze each reaction in the following metabolic pathway, as well as methods for creating microorganisms capable of producing 3HA, HMA, and / or ADA using the following metabolic pathway, are described in detail in WO 2019 / 107516.

[0020]

[0021] The present invention is characterized by reducing the function of isocitrate lyase repressor, enhancing the function of malate synthase, and / or enhancing the function of isocitrate dehydrogenase kinase / phosphatase in a microorganism capable of producing 3HA, HMA, and / or ADA.

[0022] Isocitrate lyase repressor is a protein that has the activity of suppressing the expression of genes encoding isocitrate lyase, malate synthase, and isocitrate dehydrogenase kinase / phosphatase.

[0023] A specific example of an isocitrate lyase repressor is IclR (NCBI-Protein ID: NP_418442, SEQ ID NO: 1) derived from Escherichia coli str. K-12 substr. MG1655 strain, and a specific example of a gene encoding IclR is the nucleic acid sequence of SEQ ID NO: 2.

[0024] Isocitrate lyase is an enzyme (EC 4.1.3.1) that reversibly catalyzes the reaction of producing succinic acid and glyoxylic acid from isocitrate. A specific example of isocitrate lyase is AceA (NCBI-Protein ID: NP_418439) derived from Escherichia coli str. K-12 substr. MG1655 strain.

[0025] Malate synthase is an enzyme (EC 2.3.3.9) that catalyzes the reaction of producing malic acid and CoA from glyoxylic acid and acetyl-CoA. A specific example of malate synthase is AceB (NCBI-Protein ID: NP_418438, SEQ ID NO: 35) derived from Escherichia coli str. K-12 substr. MG1655, and a specific example of a gene encoding AceB is the nucleic acid sequence of SEQ ID NO: 36.

[0026] Isocitrate dehydrogenase kinase / phosphatase is an enzyme (EC 2.7.11.5) that catalyzes the phosphorylation of isocitrate dehydrogenase, an enzyme that catalyzes the reaction of producing α-ketoglutarate and carbon dioxide from isocitrate in the TCA cycle. It is known that the catalytic activity of isocitrate dehydrogenase decreases upon phosphorylation. A specific example of isocitrate dehydrogenase kinase / phosphatase is AceK (NCBI-Protein ID: NP_418440, SEQ ID NO: 37) derived from Escherichia coli str. K-12 substr. MG1655, and a specific example of a gene encoding AceK is the nucleic acid gene of SEQ ID NO: 38.

[0027] The aceA gene encoding isocitrate lyase, the aceB gene encoding malate synthase, and the aceK gene encoding isocitrate dehydrogenase kinase / phosphatase together form the aceBAK operon. Because isocitrate lyase, malate synthase, and isocitrate dehydrogenase kinase / phosphatase catalyze reactions that form the glyoxylate cycle, which bypasses part of the TCA cycle, the aceBAK operon is also known as the glyoxylate bypass operon.

[0028] The protein encoded by the IclR gene is an isocitrate lyase repressor that functions to suppress the expression of the aceBAK operon. It is thought that by reducing the function of the isocitrate lyase repressor, the expression of the aceBAK operon is induced, and the expression of isocitrate lyase, malate synthase, and isocitrate dehydrogenase kinase / phosphatase is enhanced.

[0029] In addition, proteins other than the isocitrate lyase repressor that have the function of regulating the expression of the aceBAK operon have been reported, such as FadR (NCBI-Protein ID: NP_415705) and ArcA (NCBI-Protein ID: NP_418818) (J. Bacteriol. 1996, 178(15), 4704-4709; BMC Microbiol. 2011, 11:70).

[0030] In the present invention, the method for enhancing the glyoxylate cycle is not particularly limited as long as it is a method for reducing the function of the isocitrate lyase repressor or a method for enhancing the function of malate synthase and / or isocitrate dehydrogenase kinase / phosphatase. Methods for reducing the function of the isocitrate lyase repressor include, for example, deletion, loss-of-function mutation, or expression suppression of the gene encoding the enzyme, with deletion or expression suppression of the gene encoding the enzyme being preferred. Furthermore, the iclR gene is preferred as the isocitrate lyase repressor gene whose function is reduced.

[0031] Methods for enhancing the function of malate synthase and / or isocitrate dehydrogenase kinase / phosphatase include, for example, enhancing the catalytic activity of the enzyme itself or increasing the expression level of the enzyme, with increasing the expression level being preferred. Furthermore, the aceB gene is preferred as the malate synthase gene whose function is enhanced, and the aceK gene is preferred as the isocitrate dehydrogenase kinase / phosphatase gene.

[0032] The method for suppressing the expression of the iclR gene is not particularly limited, and examples thereof include a method of inhibiting transcription by introducing a mutation into the nucleic acid sequence of a promoter region present upstream of the gene on the genome of the microorganism, thereby reducing promoter activity, a method of inhibiting translation by introducing a base sequence that forms a secondary structure such as a hairpin into the nucleic acid sequence of mRNA obtained by transcription of the gene region, and a method of inhibiting translation by expressing an RNA nucleic acid that is a complementary strand of a portion of the gene and forming a complex with the nucleic acid molecule of the gene (J. Microbiol. Methods 2018, 154, 25-32; Nat. Biotechnol. 2013, 31(2), 170-176). In the present invention, a method of suppressing gene expression by expressing an RNA nucleic acid that is a complementary strand of a portion of the gene and forming a complex with the nucleic acid molecule of the gene to inhibit translation is preferred.

[0033] In the present invention, the catalytic activity of the enzyme malate synthase and / or isocitrate dehydrogenase kinase / phosphatase itself can be enhanced by, for example, introducing a mutation that results in the deletion, substitution, and / or insertion of a portion of an amino acid in a polypeptide having the catalytic activity of the enzyme, thereby expressing an enzyme exhibiting higher catalytic activity than before the mutation was introduced. Furthermore, methods for increasing the expression level of malate synthase and / or isocitrate dehydrogenase kinase / phosphatase are not particularly limited, and examples include introducing a gene encoding the enzyme from outside the host microorganism into the host microorganism, increasing the copy number of the gene, or modifying the promoter region or ribosome binding sequence upstream of the coding region of the gene. Methods for introducing a gene encoding the enzyme from outside the host microorganism into the host microorganism or increasing the copy number of the gene may include artificially introducing the gene originally contained in the host microorganism or introducing an exogenous gene. The aforementioned methods may be used alone or in combination to increase the expression level of the enzyme.

[0034] BMC Microbiology 2011, 11:70 discloses that the production of acetic acid and carbon dioxide is reduced by reducing the function of the isocitrate lyase repressor through deletion of the iclR gene. Furthermore, JP-A-2008-513023 discloses a method for high-level production of succinic acid, fumaric acid, malic acid, oxaloacetic acid, or glyoxylic acid, which are produced using the TCA cycle, by reducing the activity of the protein encoded by the iclR gene to reduce the function of the isocitrate lyase repressor, or by overexpressing the aceB gene or aceK gene or increasing the activity of the proteins encoded by these genes to enhance the function of malate synthase or isocitrate dehydrogenase kinase / phosphatase. On the other hand, the intermediate acetyl-CoA is essential for the production of 3HA, HMA, and / or ADA by microorganisms capable of producing 3HA, HMA, and / or ADA, and WO2022 / 102635 discloses that the productivity of 3HA and / or HMA can be improved by strengthening the reaction that produces acetyl-CoA. The reaction catalyzed by malate synthase in the glyoxylate cycle consumes acetyl-CoA and competes with the reactions for producing 3HA, HMA, and ADA. Therefore, if the function of the isocitrate lyase repressor is reduced or the function of malate synthase or isocitrate dehydrogenase kinase / phosphatase is enhanced in a microorganism capable of producing 3HA, HMA, and / or ADA, it was predicted that the by-production of acetic acid would be suppressed by strengthening the glyoxylate cycle, but the productivity of 3HA, HMA, and / or ADA would also be reduced. However, as shown in the Examples below, the unexpected effect of suppressing the by-production of acetic acid and improving the productivity of 3HA, HMA, and / or ADA was obtained.

[0035] Furthermore, the main by-products obtained by culturing microorganisms capable of producing 3HA, HMA and / or ADA include lactic acid and ethanol in addition to acetic acid. The present invention is characterized by reducing the lactic acid or ethanol production reaction in microorganisms capable of producing 3HA, HMA and / or ADA.

[0036] In the production of chemical products using microorganisms, improving the productivity of the target chemical product by reducing the by-product production reaction is a common technical means for those skilled in the art. However, as shown in the examples below, in a microorganism capable of producing 3HA, HMA, and / or ADA, simply reducing the lactic acid or ethanol production reaction results in a problem of a decrease in the production ratio of 3HA, HMA, and / or ADA relative to the by-product acetic acid. In the present invention, the production ratio of 3HA, HMA, and / or ADA relative to acetic acid can be improved by strengthening the glyoxylic acid cycle and reducing the lactic acid or ethanol production reaction.

[0037] Lactic acid is produced by the reduction of pyruvate. Specific examples of enzymes that catalyze the reduction of pyruvate to lactic acid include lactate dehydrogenase (EC 1.1.1.27, 1.1.1.28). Specific examples of lactate dehydrogenase include LdhA (NCBI-Protein ID: NP_415898, SEQ ID NO: 3) derived from Escherichia coli str. K-12 substr. MG1655, and a specific example of a gene encoding LdhA is the nucleic acid sequence of SEQ ID NO: 4.

[0038] Ethanol is produced by the reduction of acetyl-CoA. A specific example of an enzyme that catalyzes the reduction of acetyl-CoA to ethanol is alcohol dehydrogenase (EC 1.2.1.10, 1.1.1.1). A specific example of alcohol dehydrogenase is AdhE (NCBI-Protein ID: NP_415757, SEQ ID NO: 5) derived from Escherichia coli str. K-12 substr. MG1655, and a specific example of a gene encoding AdhE is the nucleic acid sequence of SEQ ID NO: 6.

[0039] In the present invention, the method for reducing the lactic acid or ethanol production reaction is not particularly limited, and examples thereof include methods for reducing the function of the aforementioned lactate dehydrogenase or alcohol dehydrogenase. The method for reducing the function of lactate dehydrogenase or alcohol dehydrogenase is not particularly limited, and examples thereof include deletion, loss-of-function mutation, or expression inhibition of the gene encoding the enzyme, with deletion or expression inhibition of the gene encoding the enzyme being preferred. The ldhA gene is preferred as the gene encoding lactate dehydrogenase whose function is reduced, and the adhE gene is preferred as the gene encoding alcohol dehydrogenase whose function is reduced.

[0040] In the present invention, the method for gene deletion or loss-of-function mutation is not particularly limited, but can be carried out by, for example, gene mutation treatment using a gene mutation agent or ultraviolet irradiation, deletion of part or all of the nucleic acid sequence by site-directed mutagenesis, introduction of a frameshift mutation into the nucleic acid sequence, insertion of a stop codon into the base sequence, etc. Alternatively, function can be lost by removing all or part of the nucleic acid sequence or replacing it with another nucleic acid sequence using genetic recombination techniques. Among these, methods that delete part or all of the nucleic acid sequence are preferred.

[0041] Furthermore, in the present invention, it is preferable to enhance the reaction of reducing 3-oxoadipyl-CoA to produce 3-hydroxyadipyl-CoA. Enhancement of the reaction of reducing 3-oxoadipyl-CoA to produce 3-hydroxyadipyl-CoA can be achieved, for example, by increasing the expression level of the enzyme that catalyzes this reaction. Methods for increasing the expression level include, for example, introducing the gene for this enzyme from outside the host microorganism into the host microorganism, increasing the copy number of the gene, or modifying the promoter region or ribosome binding sequence upstream of the coding region of the gene. These methods may be performed alone or in combination, but it is preferable to introduce the gene for this enzyme from outside the host microorganism into the host microorganism by the method described in WO 2019 / 107516.

[0042] Specific examples of 3-oxoadipyl-CoA reductases that catalyze the reaction of reducing 3-oxoadipyl-CoA to produce 3-hydroxyadipyl-CoA include enzymes classified as 3-hydroxyacyl-CoA dehydrogenases in EC 1.1.1.35, enzymes classified as 3-hydroxybutyryl-CoA dehydrogenases in EC 1.1.1.157, and enzymes that have 70% or more, preferably 80% or more, more preferably 90% or more, more preferably 95% or more, even more preferably 97% or more, and even more preferably 99% or more sequence identity to any of the amino acid sequences of SEQ ID NOS: 1 to 6 and 213 described in WO2019 / 107516 and have 3-oxoadipyl-CoA reductase activity. Specific examples include PaaH derived from Pseudomonas putida KT2440 strain (NCBI-Protein ID: NP_745425.1), PaaH derived from Escherichia coli str. K-12 substr. Examples of such polypeptides include PaaH derived from the MG1655 strain (NCBI-Protein ID: NP_415913.1), DcaH derived from the Acinetobacter baylyi ADP1 strain (NCBI-Protein ID: CAG68533.1), PaaH derived from the Serratia plymuthica NBRC102599 strain (NCBI-Protein ID: WP_063197120), and a polypeptide derived from the Serratia marcescens ATCC13880 strain (NCBI-Protein ID: KFD11732.1). The amino acid sequences of the polypeptides of SEQ ID NOs: 1 to 6 and 213 described in WO2019 / 107516 and the nucleotide sequences encoding them are shown in SEQ ID NOs: 51 to 56 and 57, and SEQ ID NOs: 17, 58 to 62 and 63, respectively.

[0043] In the present invention, "sequence identity" refers to the percentage of identical amino acids or bases in the entire overlapping amino acid sequence (including the amino acid that serves as the translation initiation point) or base sequence (including the initiation codon) in optimal alignment when two amino acid sequences or base sequences are aligned with or without gaps, and is calculated using formula (1). In formula (1), the shorter sequence length to be compared is 400 amino acids or more, and sequence identity is not defined for sequences less than 400 amino acids. Sequence identity can be easily determined using BLAST (Basic Local Alignment Search Tool), an algorithm commonly used in this field. For example, BLAST is available to anyone from websites such as NCBI (National Center for Biotechnology Information) and KEGG (Kyoto Encyclopedia of Genes and Genomes), and sequence identity can be easily determined using default parameters. Sequence identity can also be determined using a similar function built into software such as Genetyx. Sequence identity (%) = number of matches (gaps not counted) / shorter sequence length (length excluding gaps at both ends) × 100...Equation (1)

[0044] Microorganisms that inherently have the ability to produce 3-hydroxyadipic acid include the following microorganisms:

[0045] The genus Escherichia, such as Escherichia fergusonii and Escherichia coli. The genus Serratia, such as Serratia grimesi, Serratia ficaria, Serratia fonticoia, Serratia odorifera, Serratia plymuthica, Serratia entomophila, or Serratia nematodiphila. The genus Pseudomonas, such as Pseudomonas chlororaphis, Pseudomonas putida, Pseudomonas azotoformans, and Pseudomonas chlororaphis subsp. aureofaciens. The genus Hafnia, such as Hafnia alvei. Corynebacterium acetoacidophilum, Corynebacterium acetoglutamicum, Corynebacterium ammoniagenes, Corynebacterium Corynebacterium genus such as glutamicum. Bacillus genus such as Bacillus badius, Bacillus megaterium, and Bacillus roseus. Streptomyces genus such as Streptomyces vinaceus, Streptomyces karnatakensis, Streptomyces olivaceus. Cupriavidus genus such as Cupriavidus metallidurans, Cupriavidus necator, Cupriavidus oxalaticus. Acinetobacter genus such as Acinetobacter baylyi and Acinetobacter radiores Istens. Alcaligenes spp., such as Alcaligenes faecalis. The genus Nocardioides, such as Nocardioides albus. The genus Brevibacterium, such as Brevibacterium iodinum. The genus Delftia, such as Delftia acidovorans.The genus Shimwellia, such as Shimwellia blattae. The genus Aerobacter, such as Aerobacter cloacae. The genus Rhizobium, such as Rhizobium radiobacter.

[0046] Among microorganisms that inherently have the ability to produce 3-hydroxyadipic acid, in the present invention, microorganisms that do not metabolize sugars via the phosphoketolase pathway, such as those belonging to the genera Escherichia, Serratia, Hafnia, Corynebacterium, Brevibacterium, Shimwellia, and Aerobacter, are preferred, and microorganisms belonging to the genus Escherichia or Serratia are more preferably used.

[0047] Microorganisms that are presumed to inherently have the ability to produce α-hydromuconic acid include the following microorganisms:

[0048] The genus Escherichia, such as Escherichia fergusonii and Escherichia coli. The genus Serratia, such as Serratia grimesi, Serratia ficaria, Serratia fonticola, Serratia odorifera, Serratia plymuthica, Serratia entomophila, or Serratia nematodiphila. Pseudomonas fluorescens, Pseudomonas putida, Pseudomonas azotoformans, Pseudomonas chlororaphis subsp. Psuedomonas spp., such as Psuedomonas aureofaciens. Hafnia spp. such as Hafnia alvei. Bacillus genus such as Bacillus badius. Cupriavidus genus such as Cupriavidus metallidurans, Cupriavidus numazuensis, Cupriavidus oxalaticus. The genus Acinetobacter, such as Acinetobacter baylyi and Acinetobacter radioresistens. The genus Alcaligenes, such as Alcaligenes faecalis. The genus Delftia, such as Delftia acidovorans. The genus Shimwellia, such as Shimwellia blattae.

[0049] If the genetically modified microorganism of the present invention does not originally have the ability to produce 3-hydroxyadipic acid, this ability can be imparted by introducing into the microorganism an appropriate combination of nucleic acids encoding enzymes that catalyze reactions A, B, and E. If the genetically modified microorganism of the present invention does not originally have the ability to produce α-hydromuconic acid, this ability can be imparted by introducing into the microorganism an appropriate combination of nucleic acids encoding enzymes that catalyze reactions A, B, C, and F. Furthermore, if the genetically modified microorganism does not originally have the ability to produce adipic acid, this ability can be imparted by introducing into the microorganism an appropriate combination of nucleic acids encoding enzymes that catalyze reactions A, B, C, D, and G.

[0050] Microorganisms that can be used as hosts for obtaining genetically modified microorganisms in the present invention are not particularly limited as long as they are capable of being genetically modified, and may or may not be microorganisms capable of producing 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid. Examples of suitable microorganisms include Escherichia, Serratia, Hafnia, Psuedomonas, Corynebacterium, Bacillus, Streptomyces, Cupriavidus, Acinetobacter, Alcaligenes, and the like. Microorganisms belonging to the genera Escherichia, Serratia, Hafnia, and Pseudomonas are preferred, and microorganisms belonging to the genera Escherichia, Serratia, Hafnia, and Pseudomonas are particularly preferred.

[0051] The genetically modified microorganism of the present invention preferably maintains a reaction pathway for producing acetate from acetyl-CoA or pyruvate. This can be achieved, for example, by possessing a gene encoding any enzyme that catalyzes the acetate production reaction and maintaining the function of the enzyme. Examples of enzymes that catalyze the acetate production reaction include phosphate acetyltransferase (EC 2.3.1.8), which catalyzes the reaction from acetyl-CoA and phosphate to produce acetyl phosphate and CoA, acetate kinase (EC 2.7.2.1), which catalyzes the reaction to produce acetate from acetyl phosphate, and pyruvate dehydrogenase (EC 1.2.5.1), which catalyzes the reaction to produce acetate and carbon dioxide from pyruvate.

[0052] The method for introducing a gene to create the genetically modified microorganism of the present invention is not particularly limited, and methods such as incorporating the gene into an expression vector that can autonomously replicate within the microorganism and introducing it into the host microorganism, or incorporating the gene into the genome of the microorganism can be used.

[0053] The gene to be introduced may be one or more types, and gene introduction and enhancement of expression may be combined.

[0054] When a gene to be expressed or a nucleic acid fragment used to inhibit gene expression in the present invention is integrated into an expression vector or the genome of a host microorganism, the expression vector or nucleic acid to be integrated into the genome preferably comprises a promoter, a ribosome binding sequence, a gene or nucleic acid fragment to be expressed, and a transcription termination sequence. It may also contain a gene that controls promoter activity.

[0055] The promoter used in the present invention is not particularly limited as long as it can express a gene in a host microorganism, and examples thereof include a gap promoter, a trp promoter, a lac promoter, a tac promoter, a T7 promoter, and a lambda promoter (PL or PR).

[0056] When an expression vector is used to introduce a gene or enhance gene expression in the present invention, the vector is not particularly limited as long as it is capable of autonomous replication in the microorganism, and examples thereof include pBBR1MCS vector, pBR322 vector, pMW vector, pET vector, pRSF vector, pCDF vector, pACYC vector, and derivatives of the above-mentioned vectors.

[0057] In the present invention, when a nucleic acid for genome integration is used to introduce a gene or enhance gene expression, the gene is introduced using site-specific homologous recombination. The method of site-specific homologous recombination is not particularly limited, and examples thereof include a method using λ Red recombinase and FLP recombinase (Proc. Natl. Acad. Sci. USA. 2000, 97(12), 6640-6645.) and a method using λ Red recombinase and the sacB gene (Biosci. Biotechnol. Biochem. 2007, 71(12), 2905-2911.).

[0058] The method for introducing an expression vector or a nucleic acid to be integrated into a genome is not particularly limited as long as it is a method for introducing a nucleic acid into a microorganism, and examples thereof include the calcium ion method (J. Mol. Biol. 1970, 53, 159-162.) and the electroporation method (J. Bacteriol. 1988, 170, 2796-2801.).

[0059] In the method for producing 3HA, HMA, and / or ADA using the genetically modified microorganism of the present invention, the production ratio of 3HA to acetic acid is calculated according to formula (2). The production ratio of HMA to acetic acid or the production ratio of ADA to acetic acid is calculated by replacing 3HA in formula (2) with HMA or ADA.

[0060] 3HA production ratio to acetic acid=3HA production amount (g / L) / acetic acid production amount (g / L)...Equation (2).

[0061] The genetically modified microorganisms of the present invention are cultured in a medium, preferably a liquid medium, containing a carbon source that can be utilized by conventional microorganisms as a fermentation raw material. In addition to the carbon source that can be utilized by the genetically modified microorganisms, a medium containing an appropriate amount of a nitrogen source, inorganic salts, and, as needed, organic trace nutrients such as amino acids and vitamins is used. Either a natural or synthetic medium can be used as long as it contains the above nutrient sources.

[0062] The fermentation raw material is a raw material that can be metabolized by the genetically modified microorganism. "Metabolism" refers to the conversion of a chemical compound that the microorganism has taken in from outside the cell or that is produced intracellularly from another chemical compound into another chemical compound through an enzymatic reaction. Sugars are preferably used as carbon sources. Specific examples of sugars include monosaccharides such as glucose, fructose, galactose, mannose, xylose, and arabinose, disaccharides such as sucrose formed by combining these monosaccharides, polysaccharides, and starch saccharification solutions, molasses, and cellulose-containing biomass saccharification solutions containing these sugars.

[0063] The carbon sources listed above may be used alone or in combination, but it is particularly preferable to culture in a medium containing glucose. When adding a carbon source, the concentration of the carbon source in the medium is not particularly limited and can be set appropriately depending on the type of carbon source, etc. The preferred concentration of glucose is 5 to 300 g / L.

[0064] Examples of nitrogen sources that can be used in culturing the genetically modified microorganism include ammonia gas, ammonia water, ammonium salts, urea, nitrates, and other supplementary organic nitrogen sources, such as oil cakes, soybean hydrolysate, casein hydrolysate, other amino acids, vitamins, corn steep liquor, yeast or yeast extract, meat extract, peptides such as peptone, various fermentation bacteria and their hydrolysates, etc. The concentration of the nitrogen source in the medium is not particularly limited, but is preferably 0.1 to 50 g / L.

[0065] As inorganic salts used in culturing the genetically modified microorganism, for example, phosphate salts, magnesium salts, calcium salts, iron salts, manganese salts, etc. can be added as appropriate.

[0066] The culture conditions for the genetically modified microorganism to produce 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid are set by appropriately adjusting or selecting the medium having the above-mentioned component composition, culture temperature, stirring speed, pH, aeration amount, inoculation amount, etc. depending on the type of the genetically modified microorganism, external conditions, etc.

[0067] The pH range for cultivation is not particularly limited as long as the genetically modified microorganism can grow, but is preferably pH 5 to 8, more preferably pH 5.5 to 7.0.

[0068] There are no particular limitations on the range of aeration conditions during culture as long as 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid can be produced. However, in order to grow the microbial mutant well, it is preferable that oxygen remain in the gas phase and / or liquid phase in the culture vessel at least at the start of culture.

[0069] If foaming occurs during liquid culture, an antifoaming agent such as mineral oil, silicone oil, or a surfactant can be added to the medium as appropriate.

[0070] After 3-hydroxyadipic acid, α-hydromuconic acid, and / or adipic acid have been produced in the culture of the microorganism to a recoverable amount, the produced product can be recovered. The produced product can be recovered, for example, isolated, by stopping the culture when the accumulated amount has reached an appropriate level and collecting a fermentation product from the culture in accordance with a general method. Specifically, the bacterial cells can be separated by centrifugation, filtration, or the like, and then the product can be isolated from the culture by column chromatography, ion exchange chromatography, activated carbon treatment, crystallization, membrane separation, distillation, or the like. More specifically, examples of such methods include, but are not limited to, a method of adding an acid component to a salt of the product and recovering the precipitate; a method of concentrating the culture using a reverse osmosis membrane, evaporator, or the like to remove water and increase the concentration of the product, followed by cooling crystallization or adiabatic crystallization to precipitate crystals of the product and / or a salt of the product, and then obtaining crystals of the product and / or a salt of the product by centrifugation, filtration, or the like; a method of adding alcohol to the culture to convert the product into an ester, recovering the ester of the product by distillation, and then obtaining the product by hydrolysis. These recovery methods can be appropriately selected and optimized depending on the physical properties of the product, etc.

[0071] Adipic acid can be produced by reacting (hydrogenating) the α-hydromuconic acid obtained by the present invention with hydrogen in the presence of a hydrogenation catalyst. A method for producing adipic acid from a 3-hydroxyadipic acid fermentation broth is described in detail in WO 2021 / 060335. 3-hydroxyadipic acid-3,6-lactone can be prepared by dissolving 3-hydroxyadipic acid in water and adjusting the pH to 4 or less. A method for preparing 3-hydroxyadipic acid-3,6-lactone from 3-hydroxyadipic acid is described in detail in WO 2022 / 191314. Adipic acid can be produced by reacting (hydrogenating) 3-hydroxyadipic acid-3,6-lactone with hydrogen in an aqueous solvent in the presence of a hydrogenation catalyst.

[0072]

[0073] The hydrogenation catalyst preferably contains a transition metal element, and specifically, it preferably contains one or more elements selected from the group consisting of palladium, platinum, ruthenium, rhodium, rhenium, nickel, cobalt, iron, iridium, osmium, copper, and chromium, and more preferably contains one or more elements selected from the group consisting of palladium, platinum, nickel, cobalt, iron, copper, and chromium.

[0074] The hydrogenation catalyst is preferably used supported on a carrier from the viewpoints of saving the amount of metal used, increasing the active surface of the catalyst, etc. Supporting the hydrogenation catalyst on a carrier can be carried out by known methods such as impregnation, deposition / precipitation, and vapor phase support. Examples of the carrier include carbon, polymers, metal oxides, metal sulfides, zeolites, clays, heteropolyacids, solid phosphoric acid, and hydroxyapatite.

[0075] The hydrogen to be reacted with α-hydromuconic acid and / or 3-hydroxyadipic acid-3,6-lactone may be added to the reactor all at once or gradually. The partial pressure of hydrogen is not particularly limited, but if it is too low, the reaction time will be long, while if it is too high, it is undesirable from the viewpoint of equipment safety. Therefore, the partial pressure of hydrogen is preferably 0.1 MPa or more and 10 MPa or less (gauge pressure) at room temperature, more preferably 0.3 MPa or more and 5 MPa or less (gauge pressure), and even more preferably 0.5 MPa or more and 3 MPa or less (gauge pressure).

[0076] The reaction may be carried out in any reactor, such as a batch reactor, a semi-batch reactor, a continuous reactor, a continuous tubular reactor, or a trickle-bed tubular reactor. When a solid hydrogenation catalyst is used, the reaction may be carried out in any of a suspension bed, a fixed bed, a moving bed, or a fluidized bed.

[0077] The reaction temperature for hydrogenation is not particularly limited, but if it is too low, the reaction rate will be slow, and if it is too high, the amount of energy consumed will be large, which are undesirable. From these viewpoints, the reaction temperature is preferably 100 to 350°C, more preferably 120 to 300°C, even more preferably 130 to 280°C, still more preferably 140 to 250°C, even more preferably 150 to 230°C, and even more preferably 160 to 220°C.

[0078] In addition to hydrogen, the atmosphere in the reactor may contain inert gases such as nitrogen, helium, and argon, but the oxygen concentration is preferably 5% by volume or less because this can lead to deterioration of the hydrogenation catalyst and the generation of detonation gas. Furthermore, from the viewpoint of the stability of α-hydromuconic acid and / or 3-hydroxyadipic acid-3,6-lactone and adipic acid, the amount of ammonia relative to the α-hydromuconic acid and / or 3-hydroxyadipic acid-3,6-lactone raw material is preferably 5% by weight or less, more preferably 3% by weight or less, and even more preferably 0% by weight (i.e., reaction in the absence of ammonia).

[0079] The hydrogenation of α-hydromuconic acid and / or 3-hydroxyadipic acid-3,6-lactone is preferably carried out in the presence of a solvent.

[0080] Examples of solvents that can be used for the hydrogenation include methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, pentane, hexane, cyclohexane, heptane, octane, decane, dimethyl ether, diethyl ether, 1,2-dimethoxyethane, diglyme, tetrahydrofuran, dioxane, methyl acetate, ethyl acetate, n-propyl acetate, n-butyl acetate, γ-butyrolactone, N-methylpyrrolidone, dimethyl sulfoxide, and aqueous solvents. A mixed solvent of two or more of these may also be used, but from the viewpoints of economy and environmental friendliness, it is preferable to use an aqueous solvent.

[0081] In the present invention, the aqueous solvent refers to water or a mixed solvent mainly composed of water and a water-miscible organic solvent. "Mainly composed of water" means that the proportion of water in the mixed solvent is more than 50% by volume, preferably 70% by volume or more, and more preferably 90% by volume or more.

[0082] Examples of the water-miscible organic solvent include methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, 1,2-dimethoxyethane, diglyme, tetrahydrofuran, dioxane, γ-butyrolactone, N-methylpyrrolidone, dimethyl sulfoxide, dimethylformamide, dimethylacetamide, and acetone.

[0083] The pH of the aqueous solvent is not particularly limited, but in consideration of the prevention of catalyst deterioration, the prevention of by-product formation, corrosiveness to the reaction apparatus, etc., the pH is preferably 2 to 13, more preferably 3 to 11, and even more preferably 4 to 10.

[0084] When a solvent other than primary alcohols and secondary alcohols is used as the hydrogenation solvent, the carboxylic acids, carboxylates, and carboxylate esters of α-hydromuconic acid and / or 3-hydroxyadipic acid-3,6-lactone produce the corresponding adipic acid, adipate salts, and adipate esters, respectively. When a solvent containing a primary or secondary alcohol such as methanol, ethanol, n-propanol, isopropanol, n-butanol, or isobutanol is used as the hydrogenation solvent, a mixture of adipic acid, adipate salts, adipic acid monoesters, and adipic acid diesters is obtained after the reaction. In this specification, the carboxylic acids, carboxylates, and carboxylate esters of adipic acid, and mixtures thereof, are collectively referred to as "adipic acid."

[0085] The carboxylic acid of adipic acid obtained in the present invention can be further converted into an adipic acid ester by subjecting it to an esterification reaction. The esterification method is not particularly limited, and examples thereof include dehydration condensation of a carboxylic acid and an alcohol using an acid catalyst or a condensing agent, and a method using an alkylating reagent such as diazomethane or an alkyl halide.

[0086] The adipic acid obtained in the present invention can be separated and purified by ordinary unit operations such as centrifugation, filtration, membrane filtration, distillation, extraction, crystallization, and drying.

[0087] Adiponitrile can be produced from the adipic acid obtained by the present invention by a known method (for example, JP-B-61-24555). Hexamethylenediamine can be produced by hydrogenating the obtained adiponitrile by a known method (for example, JP-A-2000-508305).

[0088] Polyamides can be produced by polycondensing the adipic acid obtained by the present invention with diamines by a known method (see, for example, "Polyamide Resin Handbook," edited by Osamu Fukumoto, published by Nikkan Kogyo Shuppansha, January 1998). Specifically, by using 1,4-diaminobutane, 1,5-pentanediamine, or hexamethylenediamine as the diamine, polyamide 46, polyamide 56, and polyamide 66 can be produced, respectively.

[0089] Polyamide fibers can be produced by processing polyamides using known methods (e.g., WO 2019 / 208427). The polyamide fibers thus obtained can be used for clothing applications such as innerwear, sportswear, and casual wear, as well as industrial materials such as airbags and tire cords.

[0090] In addition, polyamide can be molded by a known method (for example, WO 2021 / 006257) to produce a polyamide molded product. The polyamide molded product thus obtained can be used for automotive parts, electrical parts, electronic parts, building materials, various containers, daily necessities, household goods, sanitary products, etc.

[0091] Reference Example 1 Preparation of Plasmids Expressing Enzymes that Catalyze the Reactions of Producing 3OA-CoA and Coenzyme A from Acetyl-CoA and Succinyl-CoA (Reaction A), Producing 3HA-CoA from 3OA-CoA (Reaction B), Producing 3-Hydroxyadipic Acid from 3HA-CoA (Reaction E), Producing α-Hydromuconic Acid from HMA-CoA (Reaction F), and Producing Adipic Acid from ADA-CoA (Reaction G) Vector pBBR1MCS-2 (ME Kovach, (1995), Gene 166:175-176), which is autonomously replicable in Escherichia coli, was cleaved with XhoI to obtain pBBR1MCS-2 / XhoI. To incorporate a constitutive expression promoter into this vector, Escherichia coli str. K-12 substr. Primers (SEQ ID NOs: 8 and 9) were designed to PCR amplify the 200b upstream region (SEQ ID NO: 7) of gapA (NCBI-Gene ID: NC_000913.3) using the genomic DNA of MG1655 as a template, and PCR was performed according to standard methods. The resulting fragment and pBBR1MCS-2 / XhoI were ligated using the "In-Fusion HD Cloning Kit" (manufactured by Takara Bio Inc.) and introduced into the E. coli strain DH5α. The plasmid was extracted from the resulting recombinant E. coli strain, and the nucleotide sequence was confirmed by standard methods. This plasmid was designated pBBR1MCS-2::Pgap. Subsequently, pBBR1MCS-2::Pgap was digested with ScaI to obtain pBBR1MCS-2::Pgap / ScaI. To amplify the gene encoding the enzyme that catalyzes reaction A, primers (SEQ ID NOs: 11 and 12) were designed to PCR amplify the full length of the acyltransferase gene pcaF (NCBI-Gene ID: 1041755, SEQ ID NO: 10) using the genomic DNA of Pseudomonas putida KT2440 strain as a template, and PCR was performed according to standard methods. The resulting fragment and pBBR1MCS-2::Pgap / ScaI were ligated using the "In-Fusion HD Cloning Kit" and introduced into Escherichia coli strain DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed by standard methods. This plasmid was designated pBBR1MCS-2::AT.Subsequently, pBBR1MCS-2::AT was digested with HpaI to obtain pBBR1MCS-2::AT / HpaI. To amplify the genes encoding the enzymes catalyzing reactions D and E, primers were designed (SEQ ID NOs: 15 and 16) for PCR amplification of a continuous sequence containing the full length of the CoA transferase genes pcaI and pcaJ (NCBI-Gene IDs: 1046613 and 1046612, SEQ ID NOs: 13 and 14) using the genomic DNA of the Pseudomonas putida KT2440 strain as a template, and PCR was performed according to standard methods. The resulting fragment and pBBR1MCS-2::AT / HpaI were ligated using the "In-Fusion HD Cloning Kit" and introduced into the Escherichia coli strain DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed by a conventional method. The resulting plasmid was designated pBBR1MCS-2::ATCT.

[0092] pBBR1MCS-2::ATCT was cleaved with ScaI to obtain pBBR1MCS-2::ATCT / ScaI. To amplify the gene encoding the enzyme that catalyzes reaction B, primers (SEQ ID NOS: 18 and 19) for amplifying the nucleic acid set forth in SEQ ID NO: 17 were designed using the genomic DNA of Serratia marcescens ATCC13880 strain as a template, and PCR was performed according to standard methods. The resulting fragment and pBBR1MCS-2::ATCT / ScaI were ligated using "In-Fusion HD Cloning Kit" (manufactured by Takara Bio Inc.) and introduced into Escherichia coli strain DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed by standard methods. This plasmid was designated pBBR1MCS-2::ATCTOR.

[0093] Reference Example 2: Preparation of template plasmid for gene expression inhibition Gene expression inhibition was performed using the method described in Nat. Biotechnol. 2013, 31(2), 170-176. To insert a 24-base nucleic acid complementary to the gene as a template plasmid for gene expression inhibition, a nucleic acid fragment (SEQ ID NO: 20) incorporating an NcoI restriction enzyme site was synthesized (manufactured by Azenta Inc.). The vector pCDF-1b, which is capable of autonomous replication in E. coli, was cleaved with XbaI and BamHI to obtain pCDF-1b / XbaI,BamHI. To incorporate the nucleic acid fragment for gene inhibition into the vector, primers for PCR amplification of the nucleic acid fragment for gene inhibition were designed (SEQ ID NOs: 21 and 22), and PCR was performed according to standard methods. The resulting fragment and pCDF-1b / XbaI, BamHI were ligated using "In-Fusion HD Cloning Kit" (manufactured by Takara Bio Inc.) and introduced into Escherichia coli strain DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed by a standard method. The resulting plasmid was designated pCDF-1b::temp.

[0094] Reference Example 3: Preparation of a Plasmid for Inhibiting iclR Gene Expression pCDF-1b::temp was cleaved with NcoI and further subjected to dephosphorylation treatment with bacterial alkaline phosphatase to obtain pCDF-1b::temp / NcoI,BAP. To incorporate a nucleic acid fragment for inhibiting iclR gene expression into this vector, a nucleic acid fragment (SEQ ID NO: 23) containing a 24-base complementary strand including the start codon of the iclR gene was synthesized (manufactured by Azenta Co., Ltd.). This fragment and pCDF-1b::temp / NcoI,BAP were ligated using "In-Fusion HD Cloning Kit" (manufactured by Takara Bio Inc.) and introduced into Escherichia coli strain DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed by standard methods. The resulting plasmid was designated pCDF-1b::iclRi.

[0095] Reference Example 4: Preparation of a Plasmid for Inhibiting Expression of the fadR Gene To incorporate a nucleic acid fragment for inhibiting expression of the fadR gene into the pCDF-1b::temp vector, a nucleic acid fragment (SEQ ID NO: 24) containing a 24-base complementary strand including the start codon of the fadR gene was synthesized (manufactured by Azenta Co., Ltd.). This fragment was ligated to pCDF-1b::temp / NcoI,BAP prepared by the method described in Reference Example 3 using "In-Fusion HD Cloning Kit" (manufactured by Takara Bio Inc.), and the resulting plasmid was introduced into the Escherichia coli strain DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed by standard methods. The resulting plasmid was designated pCDF-1b::fadRi.

[0096] Reference Example 5: Preparation and Culturing of Escherichia coli str. K-12 substr. MG1655 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid and pCDF-1b::temp Plasmid The pBBR1MCS-2::ATCTOR plasmid was introduced into Escherichia coli str. K-12 substr. MG1655 strain by electroporation. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin. The pCDF-1b::temp plasmid was introduced into the resulting strain by electroporation. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 50 μg / mL streptomycin.

[0097] One loopful of the strain was inoculated into 5 mL of LB medium (Bacto tryptone (manufactured by Difco Laboratories) 10 g / L, Bacto yeast extract (manufactured by Difco Laboratories) 5 g / L, sodium chloride 5 g / L) containing 25 μg / mL kanamycin and 50 μg / mL streptomycin adjusted to pH 7, and cultured with shaking at 30°C and 120 min-1 for 24 hours. 0.05 mL of the culture solution was added to 5 mL of medium I (glucose 10 g / L, ammonium sulfate 1 g / L, potassium phosphate 50 mM, magnesium sulfate 0.025 g / L, iron sulfate 0.0625 mg / L, manganese sulfate 2.7 mg / L, calcium chloride 0.33 mg / L, sodium chloride 1.25 g / L, Bacto tryptone 2.5 g / L, Bacto yeast extract 1.25 g / L) containing 25 μg / mL kanamycin and 50 μg / mL streptomycin adjusted to pH 6.5 in a test tube, and the mixture was cultured with shaking at 30°C and 120 min-1 for 24 hours.

[0098] The supernatant obtained by centrifuging the culture medium to remove the bacterial cells was passed through a Millex-GV membrane (0.22 μm, PVDF, manufactured by Merck), and the permeate was analyzed by HPLC and LC-MS / MS. The acetic acid and 3HA accumulated in the culture supernatant were quantitatively analyzed, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 1.

[0099] [Conditions for quantitative analysis of acetic acid by HPLC] HPLC: Shimazu Prominence (manufactured by Shimadzu Corporation) Column: Shodex Sugar SH1011 (manufactured by Showa Denko K.K.), length 300 mm, inner diameter 8 mm, particle size 6 μm Mobile phase: 0.05 M aqueous sulfuric acid Flow rate: 0.6 mL / min Column temperature: 65° C. Detector: RI.

[0100] [Conditions for quantitative analysis of 3HA by LC-MS / MS] HPLC: 1290Infinity (Agilent Technologies) Column: Synergi hydro-RP (Phenomenex), length 100 mm, inner diameter 3 mm, particle size 2.5 μm Mobile phase: 0.1% formic acid aqueous solution / methanol = 70 / 30 Flow rate: 0.3 mL / min Column temperature: 40 ° C. LC detector: 1260DAD VL+ (210 nm) MS / MS: Triple-Quad LC / MS (Agilent Technologies) Ionization method: ESI negative mode.

[0101] Reference Example 6: Preparation and Culturing of Escherichia coli str. K-12 substr. W3110 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid and pCDF-1b::temp Plasmid The pBBR1MCS-2::ATCTOR plasmid was introduced into Escherichia coli str. K-12 substr. W3110 strain by electroporation. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin. The pCDF-1b::temp plasmid was introduced into the resulting strain by electroporation. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 50 μg / mL streptomycin.

[0102] After culturing the strain in the same manner as in Reference Example 5, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 5, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 1.

[0103] Comparative Example 1: Preparation and Culturing of Escherichia coli str. K-12 substr. MG1655 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid and pCDF-1b::iclRi Plasmid To prepare the Escherichia coli str. K-12 substr. MG1655 strain in which expression of the iclR gene was suppressed, the pCDF-1b::iclRi plasmid was introduced by electroporation into the Escherichia coli str. K-12 substr. MG1655 strain into which the pBBR1MCS-2::ATCTOR plasmid had been introduced. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 50 μg / mL streptomycin.

[0104] After culturing the strain in the same manner as in Reference Example 5, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 5, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 1.

[0105] Comparative Example 2: Preparation and cultivation of ldhA gene-deleted Escherichia coli str. K-12 substr. MG1655 strain introduced with pBBR1MCS-2::ATCTOR plasmid and pCDF-1b::temp plasmid First, an Escherichia coli str. K-12 substr. MG1655 strain was prepared in which the entire ldhA gene encoding lactate dehydrogenase was deleted. The gene deletion method followed the method described in Proc. Natl. Acad. Sci. USA. 2000, 97(12):6640-6645. Escherichia coli str. K-12 substr. The pKD46 plasmid required for expressing λ Red recombinase was introduced into the MG1655 strain by electroporation. After introduction, the strain was cultured at 30°C on LB agar medium containing 50 μg / mL of ampicillin to obtain the E. coli MG1655 / pKD46 strain.

[0106] Next, a nucleic acid fragment for deleting the ldhA gene was synthesized (Azenta Co., Ltd.). This nucleic acid fragment included 500 b of the upstream region of the ldhA gene, the sacB gene, the kanamycin resistance gene, and 500 b of the downstream region of the ldhA gene on the genome of the E. coli MG1655 strain (SEQ ID NO: 25). Primers were designed for PCR amplification of the nucleic acid fragment obtained by gene synthesis (SEQ ID NOs: 26 and 27), and PCR was performed according to standard methods. The resulting fragment was purified by agarose gel electrophoresis and a nucleic acid column purification kit and used to create an ldhA gene-deleted strain. The nucleic acid fragment for deleting the ldhA gene was introduced into the E. coli MG1655 / pKD46 strain by electroporation. After introduction, the strain was cultured at 30°C on LB agar medium containing 25 μg / mL kanamycin. The resulting recombinant strain is an E. coli MG1655 / ldhA-sacB-kan strain in which the full-length ldhA gene sequence has been replaced with a sequence containing the full-length sacB gene and the kanamycin resistance gene (sacB-kan sequence).

[0107] Next, a nucleic acid fragment for removing the sacB-kan sequence was gene synthesized (Azenta Co., Ltd.). This fragment included 500 b upstream and 500 b downstream regions of the ldhA gene on the genome of the E. coli MG1655 strain (SEQ ID NO: 28). To amplify the nucleic acid fragment obtained by gene synthesis, PCR was performed according to standard methods using primers of SEQ ID NOs: 26 and 27. The resulting fragment was purified by agarose gel electrophoresis and a nucleic acid column purification kit and used to remove the sacB-kan sequence. The nucleic acid fragment for removing the sacB-kan sequence was introduced into the E. coli MG1655 / ldhA-sacB-kan strain by electroporation. After introduction, the strain was cultured at 30°C on LB agar medium containing 50 g / L sucrose. The obtained colonies were cultured on LB agar medium and LB agar medium containing 25 μg / mL kanamycin at 30° C. to select a strain lacking kanamycin resistance. The obtained strain is an E. coli MG1655 / ldhA gene-deficient strain in which the ldhA gene on the genome has been deleted.

[0108] The pBBR1MCS-2::ATCTOR plasmid was introduced into the E. coli MG1655 / ldhA gene deletion strain by electroporation. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin. The pCDF-1b::temp plasmid was introduced into the resulting strain by electroporation. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 50 μg / mL streptomycin.

[0109] After culturing the strain in the same manner as in Reference Example 5, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 5, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 1.

[0110] Comparative Example 3 Preparation and Culturing of adhE Gene-Deleted Escherichia coli str. K-12 substr. W3110 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid and pCDF-1b::temp Plasmid First, an Escherichia coli str. K-12 substr. W3110 strain was prepared in which the entire adhE gene encoding alcohol dehydrogenase was deleted. The gene deletion method followed the method described in Proc. Natl. Acad. Sci. USA. 2000, 97(12):6640-6645. Escherichia coli str. K-12 substr. The pKD46 plasmid required for expressing λ Red recombinase was introduced into the W3110 strain by electroporation. After introduction, the strain was cultured at 30°C on LB agar medium containing 50 μg / mL of ampicillin to obtain the E. coli W3110 / pKD46 strain.

[0111] Next, a nucleic acid fragment for deleting the adhE gene was synthesized (Azenta Co., Ltd.). This nucleic acid fragment included 500 b of the upstream region of the adhE gene, the sacB gene, the kanamycin resistance gene, and 500 b of the downstream region of the adhE gene on the genome of the E. coli MGW3110 strain (SEQ ID NO: 29). Primers were designed for PCR amplification of the nucleic acid fragment obtained by gene synthesis (SEQ ID NOs: 30 and 31), and PCR reactions were performed according to standard methods. The resulting fragment was purified by agarose gel electrophoresis and a nucleic acid column purification kit and used to create an adhE gene-deleted strain. The nucleic acid fragment for deleting the adhE gene was introduced into the E. coli W3110 / pKD46 strain by electroporation. After introduction, the strain was cultured at 30°C on LB agar medium containing 25 μg / mL kanamycin. The resulting recombinant strain was an E. coli W3110 / adhE-sacB-kan strain in which the full-length adhE gene sequence was replaced with a sequence containing the full-length sacB gene and the kanamycin resistance gene (sacB-kan sequence).

[0112] Next, a nucleic acid fragment for removing the sacB-kan sequence was gene synthesized (manufactured by Azenta Co., Ltd.). This fragment included 500 b upstream and 500 b downstream regions of the adhE gene on the genome of the E. coli W3110 strain (SEQ ID NO: 32). To amplify the nucleic acid fragment obtained by gene synthesis, PCR was performed according to standard methods using primers of SEQ ID NOs: 30 and 31. The resulting fragment was purified by agarose gel electrophoresis and a nucleic acid column purification kit and used to remove the sacB-kan sequence. The nucleic acid fragment for removing the sacB-kan sequence was introduced into the E. coli W3110 / adhE-sacB-kan strain by electroporation. After introduction, the strain was cultured at 30°C on LB agar medium containing 50 g / L sucrose. The obtained colonies were cultured on LB agar medium and LB agar medium containing 25 μg / mL kanamycin at 30° C. to select a strain lacking kanamycin resistance. The resulting strain is an E. coli W3110 / adhE gene-deficient strain, in which the adhE gene on the genome has been deleted.

[0113] The pBBR1MCS-2::ATCTOR plasmid was introduced into the E. coli W3110 / adhE gene deletion strain by electroporation. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin. The pCDF-1b::temp plasmid was introduced into the resulting strain by electroporation. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 50 μg / mL streptomycin.

[0114] After culturing the strain in the same manner as in Reference Example 5, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 5, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 1.

[0115] Example 1: Preparation and Culturing of an ldhA Gene-Deleted Escherichia coli str. K-12 substr. MG1655 Strain Introduced with the pBBR1MCS-2::ATCTOR Plasmid and the pCDF-1b::iclRi Plasmid The pCDF-1b::iclRi plasmid, which suppresses expression of the iclR gene, was introduced by electroporation into the ldhA gene-deleted Escherichia coli str. K-12 substr. MG1655 strain described in Comparative Example 2 and which had been introduced with the pBBR1MCS-2::ATCTOR plasmid. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 50 μg / mL streptomycin.

[0116] After culturing the strain in the same manner as in Reference Example 5, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 5, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 1.

[0117] Example 2: Preparation and Culturing of an adhE Gene-Deleted Escherichia coli str. K-12 substr. W3110 Strain Introduced with the pBBR1MCS-2::ATCTOR Plasmid and the pCDF-1b::iclRi Plasmid The pCDF-1b::iclRi plasmid, which suppresses expression of the iclR gene, was introduced by electroporation into the adhE gene-deleted Escherichia coli str. K-12 substr. W3110 strain described in Comparative Example 3 and which had been introduced with the pBBR1MCS-2::ATCTOR plasmid. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 50 μg / mL streptomycin.

[0118] After culturing the strain in the same manner as in Reference Example 5, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 5, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 1.

[0119] Comparative Example 4: Preparation and cultivation of ldhA gene-deficient Escherichia coli str. K-12 substr. MG1655 strain introduced with pBBR1MCS-2::ATCTOR plasmid and pCDF-1b::fadRi plasmid. The pCDF-1b::fadRi plasmid for suppressing expression of the fadR gene was introduced by electroporation into the ldhA gene-deficient Escherichia coli str. K-12 substr. MG1655 strain described in Comparative Example 2, into which the pBBR1MCS-2::ATCTOR plasmid had been introduced. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 50 μg / mL streptomycin.

[0120] After culturing the strain in the same manner as in Reference Example 5, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 5, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 1.

[0121] Comparative Example 5: Preparation and culture of adhE gene-deficient Escherichia coli str. K-12 substr. W3110 strain into which pBBR1MCS-2::ATCTOR plasmid and pCDF-1b::fadRi plasmid were introduced. The adhE gene-deficient Escherichia coli str. K-12 substr. W3110 strain described in Comparative Example 3 into which the pBBR1MCS-2::ATCTOR plasmid was introduced was introduced with the pCDF-1b::fadRi plasmid by electroporation to suppress expression of the fadR gene. After introduction, the strain was cultured at 37 ° C. on LB agar medium containing 25 μg / mL kanamycin and 50 μg / mL streptomycin.

[0122] After culturing the strain in the same manner as in Reference Example 5, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 5, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 1.

[0123] Example 3 Preparation and Cultivation of Escherichia coli str. K-12 substr. MG1655 Strain Deleting pykA, pykF, and ldhA Genes Introduced with pBBR1MCS-2::ATCTOR Plasmid and pCDF-1b::iclRi Plasmid First, an Escherichia coli str. K-12 substr. MG1655 strain was prepared in which the pykF and pykA genes (SEQ ID NOs: 33 and 34) encoding pyruvate kinase and the entire ldhA gene were deleted. The pykF and pykA genes were deleted according to the method described in WO2020 / 230718. The ldhA gene was deleted using the method described in Comparative Example 2. The pBBR1MCS-2::ATCTOR plasmid was introduced into the pykF, pykA, and ldhA gene-deleted strain by electroporation. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin. The pCDF-1b::iclRi plasmid, which suppresses expression of the iclR gene, was introduced into the resulting strain by electroporation. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 50 μg / mL streptomycin.

[0124] After culturing the strain in the same manner as in Reference Example 5, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 5, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 1.

[0125]

[0126] The results of Reference Example 5 and Comparative Example 1 revealed that in E. coli strains that had not been subjected to gene deletion, the production ratio of 3HA to acetic acid decreased due to suppression of iclR gene expression.

[0127] The results of Reference Examples 5 and 6 and Comparative Examples 2 and 3 revealed that the production ratio of 3HA to acetic acid was lower in E. coli strains lacking the ldhA gene or adhE gene compared to E. coli strains without gene deletion.

[0128] The results of Reference Example 5 and Example 1 showed that the production ratio of 3HA to acetic acid was improved in an E. coli strain in which the ldhA gene was deleted and expression of the iclR gene was suppressed. Furthermore, the results of Reference Example 6 and Example 2 showed that the production ratio of 3HA to acetic acid was improved in an E. coli strain in which the adhE gene was deleted and expression of the iclR gene was suppressed.

[0129] The results of Reference Example 5 and Comparative Example 4 revealed that the production ratio of 3HA to acetic acid was reduced in E. coli strains in which the ldhA gene was deleted and expression of the fadR gene was suppressed. Furthermore, the results of Reference Example 6 and Comparative Example 5 revealed that the production ratio of 3HA to acetic acid was reduced in E. coli strains in which the adhE gene was deleted and expression of the fadR gene was suppressed. This shows that suppressing the expression of the gene encoding FadR, which has the function of regulating expression of the aceBAK operon like IclR, does not have the effect of improving the production ratio of 3HA to acetic acid.

[0130] In Example 3, it was shown that the production ratio of 3HA to acetic acid was significantly improved by deleting the ldhA gene in a genetically modified microorganism in which the pyruvate kinase function was deleted as detailed in WO 2020 / 230718 and further suppressing the expression of the iclR gene.

[0131] Reference Example 7 Preparation of a Plasmid for Expressing an Enzyme Catalyzing the Reaction (Reaction C) Producing HMA-CoA from 3HA-CoA The expression vector pMW119 (manufactured by Nippon Gene Co., Ltd.) capable of autonomous replication in E. coli was cleaved with SacI to obtain pMW119 / SacI. In order to incorporate a constitutive expression promoter into this vector, primers were designed (SEQ ID NOs: 39 and 40) for PCR amplification of the upstream region 200b (SEQ ID NO: 7) of gapA (NCBI Gene ID: NC_000913.3) using the genomic DNA of Escherichia coli K-12 MG1655 as a template, and PCR was performed according to standard methods. The resulting fragment and pMW119 / SacI were ligated using "In-Fusion HD Cloning Kit" (manufactured by Takara Bio Inc.) and introduced into E. coli strain DH5α. The plasmid was extracted from the resulting recombinant E. coli strain, and the nucleotide sequence was confirmed by standard methods. This plasmid was designated pMW119::Pgap. Subsequently, pMW119::Pgap was cleaved with SphI to obtain pMW119::Pgap / SphI. To amplify the gene encoding the enzyme that catalyzes reaction C, primers were designed (SEQ ID NOs: 42 and 43) for PCR amplification of the full-length enoyl-CoA hydratase gene paaF (NCBI Gene ID: 1046932, SEQ ID NO: 41) using the genomic DNA of the Pseudomonas putida KT2440 strain as a template, and PCR was performed according to standard methods. The resulting fragment and pMW119::Pgap / SphI were ligated using "In-Fusion HD Cloning Kit" (manufactured by Takara Bio Inc.) and introduced into Escherichia coli strain DH5α. The plasmid was extracted from the resulting recombinant strain and the nucleotide sequence was confirmed by standard methods. The resulting plasmid was designated pMW119::EH.

[0132] Reference Example 8 Preparation of Plasmids for Expressing Enzymes Catalyzing the Reaction of Producing HMA-CoA from 3HA-CoA (Reaction C) and the Reaction of Producing ADA-CoA from HMA-CoA (Reaction D) pMW119::EH was cleaved with HindIII to obtain pMW119::EH / HindIII. In order to amplify the gene encoding the enzyme that catalyzes Reaction D, primers were designed (SEQ ID NOs: 45 and 46) for PCR amplification of the full length of dcaA (NCBI-Protein ID: AAL09094.1, SEQ ID NO: 44) derived from Acinetobacter baylyi ADP1 strain, and PCR was performed according to standard methods. The resulting fragment and pMW119::EH / HindIII were ligated using "In-Fusion HD Cloning Kit" (manufactured by Takara Bio Inc.) and introduced into Escherichia coli strain DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed by a standard method. The resulting plasmid was designated pMW119::EHER.

[0133] Reference Example 9: Preparation of a Plasmid for Expression of the aceB Gene pMW119::Pgap was cleaved with KpnI to obtain pMW119::Pgap / KpnI. To amplify the aceB gene encoding malate synthase, primers were designed (SEQ ID NOs: 47 and 48) for PCR amplification of the full length of aceB (SEQ ID NO: 36) derived from Escherichia coli MG1655 strain, and PCR was performed according to standard methods. The resulting fragment and pMW119::Pgap / KpnI were ligated using "In-Fusion HD Cloning Kit" (manufactured by Takara Bio Inc.) and introduced into Escherichia coli strain DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed by standard methods. The resulting plasmid was designated pMW119::aceB.

[0134] Reference Example 10: Preparation of a Plasmid for Expression of the aceK Gene pMW119::Pgap was cleaved with KpnI to obtain pMW119::Pgap / KpnI. To amplify the aceK gene encoding isocitrate dehydrogenase kinase / phosphatase, primers were designed (SEQ ID NOs: 49 and 50) for PCR amplification of the full-length aceK (SEQ ID NO: 38) derived from Escherichia coli MG1655 strain, and PCR was performed according to standard methods. The resulting fragment and pMW119::Pgap / KpnI were ligated using "In-Fusion HD Cloning Kit" (manufactured by Takara Bio Inc.) and introduced into Escherichia coli strain DH5α. The plasmid was extracted from the resulting recombinant strain, and the nucleotide sequence was confirmed by standard methods. The resulting plasmid was designated pMW119::aceK.

[0135] Reference Example 11: Preparation and Culturing of Escherichia coli str. K-12 substr. MG1655 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid, pCDF-1b::temp Plasmid, and pMW119::EH Plasmid The pMW119::EH plasmid was introduced by electroporation into the Escherichia coli str. K-12 substr. MG1655 strain introduced with the pBBR1MCS-2::ATCTOR Plasmid and pCDF-1b::temp Plasmid prepared in Reference Example 5. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin.

[0136] One loopful of the strain was inoculated into 5 mL of LB medium (Bacto tryptone (manufactured by Difco Laboratories) 10 g / L, Bacto yeast extract (manufactured by Difco Laboratories) 5 g / L, sodium chloride 5 g / L) containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin adjusted to pH 7, and cultured with shaking at 30°C and 120 min-1 for 24 hours. 0.05 mL of the culture solution was added to 5 mL of medium I (glucose 10 g / L, ammonium sulfate 1 g / L, potassium phosphate 50 mM, magnesium sulfate 0.025 g / L, iron sulfate 0.0625 mg / L, manganese sulfate 2.7 mg / L, calcium chloride 0.33 mg / L, sodium chloride 1.25 g / L, Bacto tryptone 2.5 g / L, Bacto yeast extract 1.25 g / L) containing kanamycin 25 μg / mL, streptomycin 50 μg / mL, and ampicillin 100 μg / mL and adjusted to pH 6.5 in a test tube, and the mixture was cultured with shaking at 30°C and 120 min-1 for 24 hours.

[0137] The supernatant obtained by centrifuging the culture medium to remove the bacterial cells was passed through a Millex-GV membrane (0.22 μm, PVDF, manufactured by Merck), and the permeate was analyzed by HPLC and LC-MS / MS. The acetic acid and HMA accumulated in the culture supernatant were quantitatively analyzed, and the production ratio of HMA to acetic acid calculated by substituting HMA for 3HA in formula (2) is shown in Table 2.

[0138] [Conditions for quantitative analysis of acetic acid by HPLC] The quantitative analysis of acetic acid by HPLC was carried out under the same conditions as those described in Reference Example 5.

[0139] [Conditions for quantitative analysis of HMA by LC-MS / MS] The quantitative analysis of 3HA by LC-MS / MS described in Reference Example 5 was carried out under the same conditions.

[0140] Comparative Example 6: Preparation and Culturing of IdhA Gene-Deleted Escherichia coli str. K-12 substr. MG1655 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid, pCDF-1b::temp Plasmid, and pMW119::EH Plasmid The pMW119::EH plasmid was introduced by electroporation into the ldhA gene-deleted Escherichia coli str. K-12 substr. MG1655 strain prepared in Comparative Example 2 and introduced with the pBBR1MCS-2::ATCTOR Plasmid and pCDF-1b::temp Plasmid. After the introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin.

[0141] The strain was cultured in the same manner as in Reference Example 11, and then quantitative analysis of the acetic acid and HMA accumulated in the culture supernatant was performed in the same manner as in Reference Example 11. The production ratio of HMA to acetic acid calculated by replacing 3HA in formula (2) with HMA is shown in Table 2.

[0142] Comparative Example 7: Preparation and Culturing of Escherichia coli str. K-12 substr. MG1655 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid, pCDF-1b::iclRi Plasmid, and pMW119::EH Plasmid The pMW119::EH plasmid was introduced by electroporation into the Escherichia coli str. K-12 substr. MG1655 strain introduced with the pBBR1MCS-2::ATCTOR Plasmid and pCDF-1b::iclRi Plasmid prepared in Comparative Example 1. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin.

[0143] The strain was cultured in the same manner as in Reference Example 11, and then quantitative analysis of the acetic acid and HMA accumulated in the culture supernatant was performed in the same manner as in Reference Example 11. The production ratio of HMA to acetic acid calculated by replacing 3HA in formula (2) with HMA is shown in Table 2.

[0144] Example 4 Preparation and Culturing of IdhA Gene-Deleted Escherichia coli str. K-12 substr. MG1655 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid, pCDF-1b::iclRi Plasmid, and pMW119::EH Plasmid The pMW119::EH plasmid was introduced by electroporation into the ldhA gene-deleted Escherichia coli str. K-12 substr. MG1655 strain prepared in Example 1 and introduced with the pBBR1MCS-2::ATCTOR Plasmid and pCDF-1b::iclRi Plasmid. After the introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin.

[0145] The strain was cultured in the same manner as in Reference Example 11, and then quantitative analysis of the acetic acid and HMA accumulated in the culture supernatant was performed in the same manner as in Reference Example 11. The production ratio of HMA to acetic acid calculated by replacing 3HA in formula (2) with HMA is shown in Table 2.

[0146] Reference Example 12: Preparation and Culturing of Escherichia coli str. K-12 substr. W3110 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid, pCDF-1b::temp Plasmid, and pMW119::EH Plasmid The pMW119::EH plasmid was introduced by electroporation into the Escherichia coli str. K-12 substr. W3110 strain introduced with the pBBR1MCS-2::ATCTOR plasmid and pCDF-1b::temp plasmid prepared in Reference Example 6. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin.

[0147] The strain was cultured in the same manner as in Reference Example 11, and then quantitative analysis of the acetic acid and HMA accumulated in the culture supernatant was performed in the same manner as in Reference Example 11. The production ratio of HMA to acetic acid calculated by replacing 3HA in formula (2) with HMA is shown in Table 2.

[0148] Comparative Example 8 Preparation and Culturing of adhE Gene-Deleted Escherichia coli str. K-12 substr. W3110 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid, pCDF-1b::temp Plasmid, and pMW119::EH Plasmid The pMW119::EH plasmid was introduced by electroporation into the adhE gene-deleted Escherichia coli str. K-12 substr. W3110 strain prepared in Comparative Example 3 and introduced with the pBBR1MCS-2::ATCTOR Plasmid and pCDF-1b::temp Plasmid. After the introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin.

[0149] The strain was cultured in the same manner as in Reference Example 11, and then quantitative analysis of the acetic acid and HMA accumulated in the culture supernatant was performed in the same manner as in Reference Example 11. The production ratio of HMA to acetic acid calculated by replacing 3HA in formula (2) with HMA is shown in Table 2.

[0150] Comparative Example 9: Preparation and Culturing of Escherichia coli str. K-12 substr. W3110 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid, pCDF-1b::iclRi Plasmid, and pMW119::EH Plasmid The pCDF-1b::iclRi plasmid was introduced by electroporation into the Escherichia coli str. K-12 substr. W3110 strain into which the pBBR1MCS-2::ATCTOR plasmid prepared in Reference Example 6 had been introduced. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 50 μg / mL streptomycin. The pMW119::EH plasmid was introduced into the resulting strain by electroporation. After the introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin.

[0151] The strain was cultured in the same manner as in Reference Example 11, and then quantitative analysis of the acetic acid and HMA accumulated in the culture supernatant was performed in the same manner as in Reference Example 11. The production ratio of HMA to acetic acid calculated by replacing 3HA in formula (2) with HMA is shown in Table 2.

[0152] Example 5 Preparation and Culturing of adhE Gene-Deleted Escherichia coli str. K-12 substr. W3110 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid, pCDF-1b::iclRi Plasmid, and pMW119::EH Plasmid The pMW119::EH plasmid was introduced by electroporation into the adhE gene-deleted Escherichia coli str. K-12 substr. W3110 strain prepared in Example 2 and introduced with the pBBR1MCS-2::ATCTOR Plasmid and pCDF-1b::iclRi Plasmid. After the introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin.

[0153] The strain was cultured in the same manner as in Reference Example 11, and then quantitative analysis of the acetic acid and HMA accumulated in the culture supernatant was performed in the same manner as in Reference Example 11. The production ratio of HMA to acetic acid calculated by replacing 3HA in formula (2) with HMA is shown in Table 2.

[0154]

[0155] The results of Reference Examples 11 and 12 and Comparative Examples 7 and 9 revealed that in E. coli strains that had not been subjected to gene deletion, the production ratio of HMA to acetic acid decreased due to suppression of iclR gene expression.

[0156] The results of Reference Example 11 and Comparative Example 6 revealed that the production ratio of HMA to acetic acid was lower in the E. coli strain lacking the ldhA gene than in the E. coli strain without gene deletion. Furthermore, the results of Reference Example 12 and Comparative Example 8 revealed that the production ratio of HMA to acetic acid was not improved in the E. coli strain lacking the adhE gene than in the E. coli strain without gene deletion.

[0157] The results of Reference Example 11 and Example 4 showed that the production ratio of HMA to acetic acid was improved in an E. coli strain in which the ldhA gene was deleted and the expression of the iclR gene was suppressed. Furthermore, the results of Reference Example 12 and Example 5 showed that the production ratio of HMA to acetic acid was improved in an E. coli strain in which the adhE gene was deleted and the expression of the iclR gene was suppressed.

[0158] Reference Example 13: Preparation and Culturing of Escherichia coli str. K-12 substr. MG1655 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid, pCDF-1b::temp Plasmid, and pMW119::EHER Plasmid The pMW119::EHER plasmid was introduced by electroporation into the Escherichia coli str. K-12 substr. MG1655 strain introduced with the pBBR1MCS-2::ATCTOR Plasmid and pCDF-1b::temp Plasmid prepared in Reference Example 5. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin.

[0159] One loopful of the strain was inoculated into 5 mL of LB medium (Bacto tryptone (manufactured by Difco Laboratories) 10 g / L, Bacto yeast extract (manufactured by Difco Laboratories) 5 g / L, sodium chloride 5 g / L) containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin adjusted to pH 7, and cultured with shaking at 30°C and 120 min-1 for 24 hours. 0.05 mL of the culture solution was added to 5 mL of medium I (glucose 10 g / L, ammonium sulfate 1 g / L, potassium phosphate 50 mM, magnesium sulfate 0.025 g / L, iron sulfate 0.0625 mg / L, manganese sulfate 2.7 mg / L, calcium chloride 0.33 mg / L, sodium chloride 1.25 g / L, Bacto tryptone 2.5 g / L, Bacto yeast extract 1.25 g / L) containing kanamycin 25 μg / mL, streptomycin 50 μg / mL, and ampicillin 100 μg / mL and adjusted to pH 6.5 in a test tube, and the mixture was cultured with shaking at 30°C and 120 min-1 for 24 hours.

[0160] The supernatant obtained by centrifuging the culture medium to remove the bacterial cells was passed through a Millex-GV membrane (0.22 μm, PVDF, manufactured by Merck), and the permeate was analyzed by HPLC and LC-MS / MS. The acetic acid and ADA accumulated in the culture supernatant were quantitatively analyzed, and the production ratio of ADA to acetic acid calculated by replacing 3HA in formula (2) with ADA is shown in Table 3.

[0161] [Conditions for quantitative analysis of acetic acid by HPLC] The quantitative analysis of acetic acid by HPLC was carried out under the same conditions as those described in Reference Example 5.

[0162] [Conditions for quantitative analysis of ADA by LC-MS / MS] The quantitative analysis of 3HA by LC-MS / MS described in Reference Example 5 was carried out under the same conditions.

[0163] Comparative Example 10: Preparation and Culturing of IdhA Gene-Deleted Escherichia coli str. K-12 substr. MG1655 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid, pCDF-1b::temp Plasmid, and pMW119::EHER Plasmid The pMW119::EHER plasmid was introduced by electroporation into the ldhA gene-deleted Escherichia coli str. K-12 substr. MG1655 strain prepared in Comparative Example 2 and introduced with the pBBR1MCS-2::ATCTOR Plasmid and pCDF-1b::temp Plasmid. After the introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin.

[0164] After culturing the strain in the same manner as in Reference Example 13, quantitative analysis of the acetic acid and ADA accumulated in the culture supernatant was performed in the same manner as in Reference Example 13. The production ratio of ADA to acetic acid calculated by replacing 3HA in formula (2) with ADA is shown in Table 3.

[0165] Comparative Example 11: Preparation and Culturing of Escherichia coli str. K-12 substr. MG1655 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid, pCDF-1b::iclRi Plasmid, and pMW119::EHER Plasmid The pMW119::EHER plasmid was introduced by electroporation into the Escherichia coli str. K-12 substr. MG1655 strain introduced with the pBBR1MCS-2::ATCTOR Plasmid and pCDF-1b::iclRi Plasmid prepared in Comparative Example 1. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin.

[0166] After culturing the strain in the same manner as in Reference Example 13, quantitative analysis of the acetic acid and ADA accumulated in the culture supernatant was performed in the same manner as in Reference Example 13. The production ratio of ADA to acetic acid calculated by replacing 3HA in formula (2) with ADA is shown in Table 3.

[0167] Example 6 Preparation and Culturing of IdhA Gene-Deleted Escherichia coli str. K-12 substr. MG1655 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid, pCDF-1b::iclRi Plasmid, and pMW119::EHER Plasmid The pMW119::EHER plasmid was introduced by electroporation into the ldhA gene-deleted Escherichia coli str. K-12 substr. MG1655 strain prepared in Example 1 and introduced with the pBBR1MCS-2::ATCTOR Plasmid and pCDF-1b::iclRi Plasmid. After the introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin.

[0168] After culturing the strain in the same manner as in Reference Example 13, quantitative analysis of the acetic acid and ADA accumulated in the culture supernatant was performed in the same manner as in Reference Example 13. The production ratio of ADA to acetic acid calculated by replacing 3HA in formula (2) with ADA is shown in Table 3.

[0169] Reference Example 14: Preparation and cultivation of Escherichia coli str. K-12 substr. W3110 strain into which pBBR1MCS-2::ATCTOR plasmid, pCDF-1b::temp plasmid, and pMW119::EHER plasmid have been introduced The pMW119::EHER plasmid was introduced by electroporation into the Escherichia coli str. K-12 substr. W3110 strain into which the pBBR1MCS-2::ATCTOR plasmid and pCDF-1b::temp plasmid prepared in Reference Example 6 had been introduced. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin.

[0170] After culturing the strain in the same manner as in Reference Example 13, quantitative analysis of the acetic acid and ADA accumulated in the culture supernatant was performed in the same manner as in Reference Example 13. The production ratio of ADA to acetic acid calculated by replacing 3HA in formula (2) with ADA is shown in Table 3.

[0171] Comparative Example 12: Preparation and Culturing of adhE Gene-Deleted Escherichia coli str. K-12 substr. W3110 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid, pCDF-1b::temp Plasmid, and pMW119::EHER Plasmid The pMW119::EHER plasmid was introduced by electroporation into the adhE gene-deleted Escherichia coli str. K-12 substr. W3110 strain prepared in Comparative Example 3 and introduced with the pBBR1MCS-2::ATCTOR Plasmid and pCDF-1b::temp Plasmid. After the introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin.

[0172] After culturing the strain in the same manner as in Reference Example 13, quantitative analysis of the acetic acid and ADA accumulated in the culture supernatant was performed in the same manner as in Reference Example 13. The production ratio of ADA to acetic acid calculated by replacing 3HA in formula (2) with ADA is shown in Table 3.

[0173] Comparative Example 13: Preparation and Culturing of Escherichia coli str. K-12 substr. W3110 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid, pCDF-1b::iclRi Plasmid, and pMW119::EHER Plasmid The pCDF-1b::iclRi plasmid was introduced by electroporation into the Escherichia coli str. K-12 substr. W3110 strain into which the pBBR1MCS-2::ATCTOR plasmid prepared in Reference Example 6 had been introduced. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 50 μg / mL streptomycin. The pMW119::EHER plasmid was introduced into the resulting strain by electroporation. After the introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin.

[0174] After culturing the strain in the same manner as in Reference Example 13, quantitative analysis of the acetic acid and ADA accumulated in the culture supernatant was performed in the same manner as in Reference Example 13. The production ratio of ADA to acetic acid calculated by replacing 3HA in formula (2) with ADA is shown in Table 3.

[0175] Example 7 Preparation and Culturing of adhE Gene-Deleted Escherichia coli str. K-12 substr. W3110 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid, pCDF-1b::iclRi Plasmid, and pMW119::EHER Plasmid The pMW119::EHER plasmid was introduced by electroporation into the adhE gene-deleted Escherichia coli str. K-12 substr. W3110 strain into which the pBBR1MCS-2::ATCTOR plasmid and the pCDF-1b::iclRi plasmid prepared in Example 2 had been introduced. After the introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin, 50 μg / mL streptomycin, and 100 μg / mL ampicillin.

[0176] After culturing the strain in the same manner as in Reference Example 13, quantitative analysis of the acetic acid and ADA accumulated in the culture supernatant was performed in the same manner as in Reference Example 13. The production ratio of ADA to acetic acid calculated by replacing 3HA in formula (2) with ADA is shown in Table 3.

[0177]

[0178] The results of Reference Examples 13 and 14 and Comparative Examples 11 and 13 revealed that in E. coli strains that had not been subjected to gene deletion, the effect of suppressing the expression of the iclR gene in improving the production ratio of ADA to acetic acid was not observed.

[0179] The results of Reference Example 13 and Comparative Example 10 revealed that the ldhA gene-deleted E. coli strain reduced the ADA production ratio to acetic acid compared to the non-gene-deleted E. coli strain. Furthermore, the results of Reference Example 14 and Comparative Example 12 revealed that the adhE gene-deleted E. coli strain did not improve the ADA production ratio to acetic acid compared to the non-gene-deleted E. coli strain.

[0180] The results of Reference Example 13 and Example 6 showed that the production ratio of ADA to acetic acid was improved in an E. coli strain in which the ldhA gene was deleted and the expression of the iclR gene was suppressed. Furthermore, the results of Reference Example 14 and Example 7 showed that the production ratio of ADA to acetic acid was improved in an E. coli strain in which the adhE gene was deleted and the expression of the iclR gene was suppressed.

[0181] Reference Example 15: Preparation and cultivation of Escherichia coli str. K-12 substr. MG1655 strain into which pBBR1MCS-2::ATCTOR plasmid and pMW119::Pgap plasmid have been introduced The pMW119::Pgap plasmid was introduced by electroporation into the Escherichia coli str. K-12 substr. MG1655 strain into which the pBBR1MCS-2::ATCTOR plasmid prepared in Reference Example 5 had been introduced. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 100 μg / mL ampicillin.

[0182] One loopful of the strain was inoculated into 5 mL of LB medium (Bacto tryptone (manufactured by Difco Laboratories) 10 g / L, Bacto yeast extract (manufactured by Difco Laboratories) 5 g / L, sodium chloride 5 g / L) containing 25 μg / mL kanamycin and 100 μg / mL ampicillin adjusted to pH 7, and cultured with shaking at 30°C and 120 min-1 for 24 hours. 0.05 mL of the culture solution was added to 5 mL of medium I (glucose 10 g / L, ammonium sulfate 1 g / L, potassium phosphate 50 mM, magnesium sulfate 0.025 g / L, iron sulfate 0.0625 mg / L, manganese sulfate 2.7 mg / L, calcium chloride 0.33 mg / L, sodium chloride 1.25 g / L, Bacto tryptone 2.5 g / L, Bacto yeast extract 1.25 g / L) containing 25 μg / mL kanamycin and 100 μg / mL ampicillin adjusted to pH 6.5 in a test tube, and the mixture was cultured with shaking at 30°C and 120 min-1 for 24 hours.

[0183] The supernatant obtained by centrifuging the culture medium to remove the bacterial cells was passed through a Millex-GV membrane (0.22 μm, PVDF, manufactured by Merck), and the permeate was analyzed by HPLC and LC-MS / MS. The acetic acid and 3HA accumulated in the culture supernatant were quantitatively analyzed, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 4.

[0184] [Conditions for quantitative analysis of acetic acid by HPLC] The quantitative analysis of acetic acid by HPLC was carried out under the same conditions as those described in Reference Example 5.

[0185] [Conditions for quantitative analysis of 3HA by LC-MS / MS] The quantitative analysis of 3HA by LC-MS / MS was carried out under the same conditions as those described in Reference Example 5.

[0186] Comparative Example 14: Preparation and cultivation of ldhA gene-deleted Escherichia coli str. K-12 substr. MG1655 strain into which pBBR1MCS-2::ATCTOR plasmid and pMW119::Pgap plasmid were introduced. The pMW119::Pgap plasmid was introduced by electroporation into the ldhA gene-deleted Escherichia coli str. K-12 substr. MG1655 strain into which the pBBR1MCS-2::ATCTOR plasmid prepared in Comparative Example 2 had been introduced. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 100 μg / mL ampicillin.

[0187] After culturing the strain in the same manner as in Reference Example 15, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 15, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 4.

[0188] Comparative Example 15: Preparation and cultivation of Escherichia coli str. K-12 substr. MG1655 strain introduced with pBBR1MCS-2::ATCTOR plasmid and pMW119::aceB plasmid The pMW119::aceB plasmid was introduced by electroporation into the Escherichia coli str. K-12 substr. MG1655 strain introduced with the pBBR1MCS-2::ATCTOR plasmid prepared in Reference Example 5. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 100 μg / mL ampicillin.

[0189] After culturing the strain in the same manner as in Reference Example 15, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 15, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 4.

[0190] Example 8 Preparation and Culturing of an ldhA Gene-Deleted Escherichia coli str. K-12 substr. MG1655 Strain Introduced with the pBBR1MCS-2::ATCTOR Plasmid and the pMW119::aceB Plasmid The pMW119::aceB plasmid was introduced by electroporation into the ldhA gene-deleted Escherichia coli str. K-12 substr. MG1655 strain into which the pBBR1MCS-2::ATCTOR plasmid prepared in Comparative Example 2 had been introduced. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 100 μg / mL ampicillin.

[0191] After culturing the strain in the same manner as in Reference Example 15, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 15, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 4.

[0192] Comparative Example 16: Preparation and Culturing of Escherichia coli str. K-12 substr. MG1655 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid and pMW119::aceK Plasmid The pMW119::aceK plasmid was introduced by electroporation into the Escherichia coli str. K-12 substr. MG1655 strain introduced with the pBBR1MCS-2::ATCTOR plasmid prepared in Reference Example 5. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 100 μg / mL ampicillin.

[0193] After culturing the strain in the same manner as in Reference Example 15, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 15, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 4.

[0194] Example 9 Preparation and Culturing of an ldhA Gene-Deleted Escherichia coli str. K-12 substr. MG1655 Strain Introduced with the pBBR1MCS-2::ATCTOR Plasmid and the pMW119::aceK Plasmid The pMW119::aceK plasmid was introduced by electroporation into the ldhA gene-deleted Escherichia coli str. K-12 substr. MG1655 strain into which the pBBR1MCS-2::ATCTOR plasmid prepared in Comparative Example 2 had been introduced. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 100 μg / mL ampicillin.

[0195] After culturing the strain in the same manner as in Reference Example 15, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 15, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 4.

[0196] Reference Example 16: Preparation and cultivation of Escherichia coli str. K-12 substr. W3110 strain into which pBBR1MCS-2::ATCTOR plasmid and pMW119::Pgap plasmid have been introduced The pMW119::Pgap plasmid was introduced by electroporation into the Escherichia coli str. K-12 substr. W3110 strain into which the pBBR1MCS-2::ATCTOR plasmid prepared in Reference Example 6 had been introduced. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 100 μg / mL ampicillin.

[0197] After culturing the strain in the same manner as in Reference Example 15, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 15, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 4.

[0198] Comparative Example 17: Preparation and culture of adhE gene-deleted Escherichia coli str. K-12 substr. W3110 strain into which the pBBR1MCS-2::ATCTOR plasmid and the pMW119::Pgap plasmid were introduced. The pMW119::Pgap plasmid was introduced by electroporation into the adhE gene-deleted Escherichia coli str. K-12 substr. W3110 strain into which the pBBR1MCS-2::ATCTOR plasmid prepared in Comparative Example 3 had been introduced. After introduction, the strain was cultured at 37 ° C. on LB agar medium containing 25 μg / mL kanamycin and 100 μg / mL ampicillin.

[0199] After culturing the strain in the same manner as in Reference Example 15, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 15, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 4.

[0200] Comparative Example 18: Preparation and Culturing of Escherichia coli str. K-12 substr. W3110 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid and pMW119::aceB Plasmid The pMW119::aceB plasmid was introduced by electroporation into the Escherichia coli str. K-12 substr. W3110 strain into which the pBBR1MCS-2::ATCTOR plasmid prepared in Reference Example 6 had been introduced. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 100 μg / mL ampicillin.

[0201] After culturing the strain in the same manner as in Reference Example 15, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 15, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 4.

[0202] Example 10 Preparation and Culturing of an adhE Gene-Deleted Escherichia coli str. K-12 substr. W3110 Strain Introduced with the pBBR1MCS-2::ATCTOR Plasmid and the pMW119::aceB Plasmid The pMW119::aceB plasmid was introduced by electroporation into the adhE gene-deleted Escherichia coli str. K-12 substr. W3110 strain into which the pBBR1MCS-2::ATCTOR plasmid prepared in Comparative Example 3 had been introduced. After introduction, the strain was cultured at 37 ° C. on LB agar medium containing 25 μg / mL kanamycin and 100 μg / mL ampicillin.

[0203] After culturing the strain in the same manner as in Reference Example 15, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 15, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 4.

[0204] Comparative Example 19: Preparation and Culturing of Escherichia coli str. K-12 substr. W3110 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid and pMW119::aceK Plasmid The pMW119::aceK plasmid was introduced by electroporation into the Escherichia coli str. K-12 substr. W3110 strain into which the pBBR1MCS-2::ATCTOR plasmid prepared in Reference Example 6 had been introduced. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 100 μg / mL ampicillin.

[0205] After culturing the strain in the same manner as in Reference Example 15, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 15, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 4.

[0206] Example 11 Preparation and Culturing of adhE Gene-Deleted Escherichia coli str. K-12 substr. W3110 Strain Introduced with pBBR1MCS-2::ATCTOR Plasmid and pMW119::aceK Plasmid The pMW119::aceK plasmid was introduced by electroporation into the adhE gene-deleted Escherichia coli str. K-12 substr. W3110 strain into which the pBBR1MCS-2::ATCTOR plasmid prepared in Comparative Example 3 had been introduced. After introduction, the strain was cultured at 37°C on LB agar medium containing 25 μg / mL kanamycin and 100 μg / mL ampicillin.

[0207] After culturing the strain in the same manner as in Reference Example 15, quantitative analysis of the acetic acid and 3HA accumulated in the culture supernatant was performed in the same manner as in Reference Example 15, and the production ratio of 3HA to acetic acid calculated using formula (2) is shown in Table 4.

[0208]

[0209] The results of Reference Examples 15 and 16 and Comparative Examples 15 and 18 revealed that in E. coli strains that had not been subjected to gene deletion, the production ratio of 3HA to acetic acid decreased due to an increase in the expression level of the aceB gene.

[0210] The results of Reference Examples 15 and 16 and Comparative Examples 16 and 19 revealed that in E. coli strains that had not been subjected to gene deletion, the production ratio of 3HA to acetic acid decreased due to an increase in the expression level of the aceK gene.

[0211] The results of Reference Examples 15 and 16 and Comparative Examples 14 and 17 revealed that the production ratio of 3HA to acetic acid was lower in E. coli strains lacking the ldhA gene or adhE gene compared to E. coli strains without gene deletion.

[0212] The results of Reference Example 15 and Examples 8 and 9 showed that the production ratio of 3HA to acetic acid was improved in E. coli strains in which the ldhA gene was deleted and the expression level of the aceB gene or the aceK gene was increased. Furthermore, the results of Reference Example 16 and Examples 10 and 11 showed that the production ratio of 3HA to acetic acid was improved in E. coli strains in which the adhE gene was deleted and the expression level of the aceB gene or the aceK gene was increased.

Claims

1. A genetically modified microorganism having the ability to produce 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid, in which the glyoxylic acid cycle is enhanced and the reaction for producing lactic acid or ethanol is reduced.

2. The genetically modified microorganism according to claim 1, wherein the enhancement of the glyoxylate cycle is a reduction in the function of isocitrate lyase repressor, an enhancement in the function of malate synthase, and / or an enhancement in the function of isocitrate dehydrogenase kinase / phosphatase.

3. The genetically modified microorganism according to claim 1 or 2, wherein the enhancement of the glyoxylate cycle is any one of the following (i) to (iii): (i) a reduction in the function of isocitrate lyase repressor by deletion, loss-of-function mutation, or suppression of expression of the iclR gene, (ii) an enhancement of the function of malate synthase by increasing the expression level of the aceB gene, or (iii) an enhancement of the function of isocitrate dehydrogenase kinase / phosphatase by increasing the expression level of the aceK gene.

4. The genetically modified microorganism according to any one of claims 1 to 3, wherein the decrease in the lactic acid production reaction is due to a deletion, loss-of-function mutation, or suppression of expression of a gene encoding lactate dehydrogenase.

5. The genetically modified microorganism of claim 4, wherein the gene encoding lactate dehydrogenase is the ldhA gene.

6. The genetically modified microorganism according to any one of claims 1 to 5, wherein the decrease in the ethanol production reaction is due to a deletion, loss-of-function mutation, or suppression of expression of a gene encoding alcohol dehydrogenase.

7. The genetically modified microorganism according to claim 6, wherein the gene encoding the alcohol dehydrogenase is the adhE gene.

8. The genetically modified microorganism according to any one of claims 1 to 7, further comprising an enhanced reaction for reducing 3-oxoadipyl-CoA to produce 3-hydroxyadipyl-CoA.

9. The genetically modified microorganism according to any one of claims 1 to 8, which maintains a reaction pathway for producing acetate from acetyl-CoA or pyruvate.

10. A method for producing 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid, comprising a step of culturing the genetically modified microorganism according to any one of claims 1 to 9.

11. A method for producing adipic acid, comprising the steps of producing 3-hydroxyadipic acid and / or α-hydromuconic acid by the method according to claim 10, and reacting the acid with hydrogen in the presence of a hydrogenation catalyst (hydrogenation step).

12. A method for producing a polyamide, comprising the steps of producing adipic acid by the method according to claim 10 or 11, and polycondensing adipic acid and a diamine.

13. The method for producing a polyamide according to claim 12, wherein the diamine is a diamine containing 1,4-butanediamine, 1,5-pentanediamine or hexamethylenediamine.

14. 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid obtained by culturing the genetically modified microorganism according to any one of claims 1 to 9.

15. Adipic acid obtained by a process comprising the steps of producing 3-hydroxyadipic acid and / or α-hydromuconic acid by the method according to claim 10, and reacting the acid with hydrogen in the presence of a hydrogenation catalyst (hydrogenation step).

16. A polyamide obtained from a process comprising the steps of producing adipic acid by the method of claim 10 or 11, and polycondensing adipic acid and a diamine.

Citation Information

Patent Citations

  • high succinate-producing bacteria

    JP2008513023A

  • Polyamide resin and polyamide resin composition

    JP2009191156A

  • Gene-modified microorganism for producing 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid, and production method for said chemical products

    WO2019107516A1

  • Genetically modified microorganism for producing 3-hydroxyhexanedioic acid, (e)-hex-2-enedioic acid and / or hexanedioic acid, and production method for said chemicals

    WO2020230718A1

  • Genetically modified microorganism for producing 3-hydroxyadipic acid and / or α-hydromuconic acid, and method for producing chemical product

    WO2022102635A1